These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7845750)

  • 21. Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.
    Neely MN; Kato L; Youn G; Kraler L; Bayard D; van Guilder M; Schumitzky A; Yamada W; Jones B; Minejima E
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between vancomycin dosage and serum trough vancomycin concentrations in pediatric patients with cystic fibrosis.
    Durham SH; Garza KB; Eiland LS
    Am J Health Syst Pharm; 2016 Jul; 73(13):969-74. PubMed ID: 27325878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a Bayesian method for predicting vancomycin dosing.
    Burton ME; Gentle DL; Vasko MR
    DICP; 1989 Apr; 23(4):294-300. PubMed ID: 2728513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Bayesian forecasting of plasma vancomycin concentration using time-dependent pharmacokinetics].
    Nakamura T; Wakaki N; Kimura Y; Goto N; Masada M
    Yakugaku Zasshi; 1996 Nov; 116(11):876-83. PubMed ID: 8981831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster.
    Guay DR; Vance-Bryan K; Gilliland S; Rodvold K; Rotschafer J
    J Clin Pharmacol; 1993 Oct; 33(10):918-22. PubMed ID: 8227461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian forecasting of serum vancomycin concentrations in neonates and infants.
    Rodvold KA; Gentry CA; Plank GS; Kraus DM; Nickel E; Gross JR
    Ther Drug Monit; 1995 Jun; 17(3):239-46. PubMed ID: 7624919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens.
    Hurst AK; Yoshinaga MA; Mitani GH; Foo KA; Jelliffe RW; Harrison EC
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1165-71. PubMed ID: 2393277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters.
    Teramachi H; Hatakeyama H; Matsushita R; Imai Y; Miyamoto K; Tsuji A
    Biol Pharm Bull; 2002 Oct; 25(10):1333-8. PubMed ID: 12392090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models.
    Pryka RD; Rodvold KA; Garrison M; Rotschafer JC
    Ther Drug Monit; 1989; 11(4):450-4. PubMed ID: 2741194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PK/PD of vancomycin in patients with severe acute pancreatitis combined with augmented renal clearance].
    He J; Mao E; Jing F; Jiang H; Xu W; Yang W; Chen E
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Sep; 29(9):810-814. PubMed ID: 28936957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods.
    Tsuji Y; Hiraki Y; Mizoguchi A; Sadoh S; Sonemoto E; Kamimura H; Karube Y
    J Clin Pharm Ther; 2009 Aug; 34(4):465-72. PubMed ID: 19583680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children.
    Giachetto GA; Telechea HM; Speranza N; Oyarzun M; Nanni L; Menchaca A
    Pediatr Crit Care Med; 2011 Nov; 12(6):e250-4. PubMed ID: 21057350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vancomycin pharmacokinetics in middle-aged and elderly men.
    Leonard AE; Boro MS
    Am J Hosp Pharm; 1994 Mar; 51(6):798-800. PubMed ID: 8010319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience with Continuous Infusion Vancomycin Dosing in a Large Pediatric Hospital.
    Hurst AL; Baumgartner C; MacBrayne CE; Child J
    J Pediatric Infect Dis Soc; 2019 May; 8(2):174-179. PubMed ID: 29718415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.
    Jelliffe R; Bayard D; Milman M; Van Guilder M; Schumitzky A
    Ther Drug Monit; 2000 Jun; 22(3):346-53. PubMed ID: 10850404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of a pediatric population pharmacokinetic model for vancomycin.
    Hahn A; Frenck RW; Zou Y; Vinks AA
    Ther Drug Monit; 2015 Jun; 37(3):413-6. PubMed ID: 25423413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients.
    Wrishko RE; Levine M; Khoo D; Abbott P; Hamilton D
    Ther Drug Monit; 2000 Oct; 22(5):522-31. PubMed ID: 11034256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic external evaluation of reported population pharmacokinetic models of vancomycin in Chinese children and adolescents.
    Lv C; Lu J; Jing L; Liu TT; Chen M; Zhang R; Li C; Zhou S; Wei Y; Chen Y
    J Clin Pharm Ther; 2021 Jun; 46(3):820-831. PubMed ID: 33751618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of vancomycin dosing for complicated infections in pediatric patients.
    Durham SH; Simmons ML; Mulherin DW; Foland JA
    Hosp Pediatr; 2015 May; 5(5):276-81. PubMed ID: 25934812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vancomycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.